

# Isolator's total breakdown in a production unit:

how to face the emergency?

M. Fontaine ; L. Eyquem ; B. Laluque



Pharmacie à Usage Intérieur, Centre Hospitalier Jacques Cœur, 18000 Bourges

## Introduction

Chemotherapy Reconstitution Unit

2 overpressure isolators
40 preparation a day
August 2022
Isolator's 1 failure
Constrained production
in 1 isolator

Isolator's 2 failure
Isolator's 2 failure



- Managing the risks associated with an unexpectedly degraded mode

## Material and methods

October 20 2022 = total breakdown

## Multi-disciplinary meeting:

- pharmacist
- oncologists
- coordinator nurse
- hospital management

Decision to maintain the original program as far as possible



#### Identified risks

- Bacteriological contamination of preparations for immunocompromised patients
- Agents exposure to cytotoxics
- Defect of the MSC II zone : polluted air not evacuated
- Unprecedented and poorly anticipated situation
- Duration = 12 days of production

## **Results - Discussion**

- 1 Proposed degraded methods:
  - Closed system:
    - ✓ Connects to all vial used.
    - ✓ Toxi-Guard® air-cleaning technology = guaranted sterility for the preparation and the environment, safety for the operator
  - Laminar flow hood:
    - ✓ Bacteriological risk under control
    - X Non-recycled air = risk of cytotoxics exposure for the operator
- 2- Selected method:

Combining the two methods → closed system used under the laminar flow hood

## Tevadaptor® (syringe adaptor + vial adaptor)

https://www.bbraun.co.uk/en/products-and-therapies/infusiontherapy/tevadaptor-.html#chemfort-components



Average production: 40 preparations/day = No reduction in production

## Excess cost:



4,000 euros : closed systems (not usually used)

• 3,000 euros : leftover unused products for safety resons

This exceptionnal situation enabled us to measure the ability of our medical and pharmaceutical teams to adapt and collaborate and to prepare for:

- ✓ a potential recurrence of the incident
- ✓ isolator's replacement in autumn 2023

A declaration of serious adverse event was notified to the French regional health agency